Citigroup’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-7,440
| Closed | -$296K | – | 7497 |
|
|
2016
Q3 | $296K | Buy |
+7,440
| New | +$83K | ﹤0.01% | 4363 |
|
|
2016
Q2 | – | Sell |
-1,838
| Closed | -$15K | – | 7757 |
|
|
2016
Q1 | $15K | Buy |
1,838
+1,819
| +9,574% | +$13.7K | ﹤0.01% | 6683 |
|
|
2015
Q4 | $0 | Sell |
19
-89
| -82% | -$925 | ﹤0.01% | 8130 |
|
|
2015
Q3 | $1K | Sell |
108
-890
| -89% | -$12.5K | ﹤0.01% | 7301 |
|
|
2015
Q2 | $18K | Buy |
998
+904
| +962% | +$13.2K | ﹤0.01% | 6180 |
|
|
2015
Q1 | $1K | Sell |
94
-201
| -68% | -$2.16K | ﹤0.01% | 7129 |
|
|
2014
Q4 | $2K | Buy |
295
+235
| +392% | +$2.02K | ﹤0.01% | 6907 |
|
|
2014
Q3 | $1K | Buy |
60
+46
| +329% | +$909 | ﹤0.01% | 6996 |
|
|
2014
Q2 | $1K | Buy |
+14
| New | +$852 | ﹤0.01% | 7036 |
|
|
2013
Q4 | – | Sell |
-136
| Closed | -$8K | – | 7275 |
|
|
2013
Q3 | $8K | Buy |
+136
| New | +$7.13K | ﹤0.01% | 6306 |
|
Citigroup's TBRA Position: Q4 2016 in Review
Citigroup sold out of Tobira Therapeutics, Inc. Common Stock (TBRA) in Q4 2016, closing a stake of 7,440 shares — an estimated $296K sold.
Citigroup first reported a position in TBRA in Q3 2013 and held it in 10 quarters. The position peaked at $296K in Q3 2016. 0 funds tracked by Wall St. Rank hold TBRA as of Q4 2016.
- Citigroup reported no remaining Tobira Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
- Citigroup sold 7,440 Tobira Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $296K.
- Citigroup first reported a position in Tobira Therapeutics, Inc. Common Stock in Q3 2013 and held it in 10 quarters.
- Citigroup's Tobira Therapeutics, Inc. Common Stock position peaked at $296K in Q3 2016.
- 0 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q4 2016.
Based on Citigroup's 13F filing for Q4 2016, filed 10 Feb 2017.